Compare Dropbox Inc (DBX) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Cassava Sciences Inc — how do they compare? Dropbox Inc trades at $34.15 (market cap $7.42B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Dropbox Inc is far larger — about 188.3× Cassava Sciences Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Cassava Sciences Inc for 37 Days on average.
| DBX | FLNA | |
|---|---|---|
Market Cap | $7.42B | $39.40M |
Volume | 3,061,580 | 759,018 |
Sector | Technology | Health |
52-Week High | $37.74 | $4.64 |
52-Week Low | $22.06 | $0.68 |
Typical Hold Time | 97 Days | 37 Days |
Enterprise Value | $10.29B | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $33.08, down 1.93% today, showing bearish technical signals with resistance at $34. Fundamentally, the company maintains strong profitability with 79.72% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights insider selling and a security breach affecting 5,000 accounts in August 2026, while analyst sentiment remains divided with a consensus price target of $26.83.
The outlook remains cautious due to mixed analyst ratings and insider selling activity. While strong cash flow generation and consistent earnings beats provide support, valuation concerns and stagnant revenue growth near $2.5B present headwinds. Key risks include competitive pressures in cloud storage and execution challenges in maintaining market position.
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
